Assessing Grifols (BME:GRF) Valuation After Recent Share Price Weakness And Perceived Discount
Is Grifols (BME:GRF) Offering Value After Recent Share Price Swings?
Green Rise Announces Certain Management Changes
Green Rise Foods Announces Q3 Fiscal 2025 Financial Results
Eagle Capital Growth Fund Declares Year-End Distribution of $0.85 Per Share in Cash
Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash
Grifols price target lowered to EUR 15.50 from EUR 15.60 at Berenberg
Grifols receives FDA approval to treat surgical bleeding with FS solution
Green Rise Capital Corp. Reports Strong Q3 Growth
Grifols partners with BARDA for PoC testing of ocular immunoglobulin
GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
Grifols Trading Suspension Lifted by NSMC
Grifols Reports Robust H1 2024 Financial Growth
Grifols Announces Financial Restatements; Results Stand Firm
Grifols S.A. Trading Suspended Amidst Information Withholding
Grifols receives expanded XEMBIFY? (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
Grifols Prepares for Potential Acquisition Offer
Grifols Strengthens Financial Position for 2024
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
Grifols Concludes $1.8 Billion Stake Sale to Haier
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.